Article

Expected increase in prevalence of HCV-related cirrhosis and its complications in the United States: no effect of current antiviral treatment coverage?

Inserm U995, Amphi J&K, boulevard du Professeur-Jules-Leclercq, 59045 Lille, France.
Gastroentérologie Clinique et Biologique (impact factor: 0.8). 11/2010; 34(11):577-9. DOI:10.1016/j.gcb.2010.09.004 pp.577-9
Source: PubMed

ABSTRACT Davis et al. projected the future prevalence of chronic hepatitis C (CHC) and its complications in the United States, using a multicohort natural history model with a tree model. First, the model predicted that in 2010 many patients have already progressed to F4, including to decompensated cirrhosis and HCC. Second, the model emphasized that cirrhosis and its complications are most common after 60 years old, regardless of when the infection occurred. Finally, the model showed that current treatment patterns will have little effect on the incidence of the complications hepatitis C.

0 0
 · 
0 Bookmarks
 · 
23 Views
  • Source
    Article: A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.
    Holly Hagan, Enrique R Pouget, Don C Des Jarlais
    [show abstract] [hide abstract]
    ABSTRACT: High rates of hepatitis C virus (HCV) transmission are found in samples of people who inject drugs (PWID) throughout the world. The objective of this paper was to meta-analyze the effects of risk-reduction interventions on HCV seroconversion and identify the most effective intervention types. We performed a systematic review and meta-analysis of published and unpublished studies. Eligible studies reported on the association between participation in interventions intended to reduce unsafe drug injection and HCV seroconversion in samples of PWID. The meta-analysis included 26 eligible studies of behavioral interventions, substance-use treatment, syringe access, syringe disinfection, and multicomponent interventions. Interventions using multiple combined strategies reduced risk of seroconversion by 75% (pooled relative risk, .25; 95% confidence interval, .07-.83). Effects of single-method interventions ranged from .6 to 1.6. Interventions using strategies that combined substance-use treatment and support for safe injection were most effective at reducing HCV seroconversion. Determining the effective dose and combination of interventions for specific subgroups of PWID is a research priority. However, our meta-analysis shows that HCV infection can be prevented in PWID.
    The Journal of Infectious Diseases 07/2011; 204(1):74-83. · 6.41 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

60 years old
 
chronic hepatitis C
 
cirrhosis
 
current treatment patterns
 
Davis
 
decompensated cirrhosis
 
future prevalence
 
HCC
 
model emphasized
 
multicohort natural history model
 
patients
 
United States
 

S Deuffic-Burban